$BNS — BUY 📊 | 6 MONTHS THESIS

$BNS — BUY 📊 | 6 MONTHS THESIS 🎯 latest | Rev $9.6B | EPS $2.02 vs $1.94 🟢 💡 Consensus expected prolonged loan losses in Latin America and NIM compression; the beat and forward outlook indicate a peak in credit costs. The market underappreciates the earnings inflection, creating an opportunity for P/E and P/B expansion. 📉 Reward/risk: 2.14:1 🏢 Business Quality: 6/10 - Diversified Canadian bank with solid domestic franchise but elevated international risk and historically lower ROE versus peers 📊 Valuation: cheap relative to Canadian peers (P/E 12-13x) and own historical average (11x), trading at 10.7x trailing EPS and ~1.4x P/B; normalized earnings of... 🔮 Catalyst: Next quarterly earnings release 💰 Entry: $86.37, stop $80.0, target $100.0 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/BNS0618

🎯 latest | Rev $9.6B | EPS $2.02 vs $1.94 🟢